Importance Despite the use of a cytomegalovirus (CMV) prevention strategy of antiviral
prophylaxis for high-risk CMV-seronegative liver transplant recipients with seropositive …

Cytomegalovirus (CMV) is one of the most common viral pathogens causing clinical disease
in liver transplant recipients, and contributing to substantial morbidity and occasional …

Clinical practice guidelines recommend antiviral prophylaxis to cytomegalovirus (CMV)
donor‐positive/recipient‐negative (D+/R−) liver transplant recipients. We assessed the …

Cytomegalovirus (CMV) is a common viral pathogen that influences the outcome of liver
transplantation. In addition to the direct effects of CMV syndrome and tissue-invasive …

Background. The incidence and impact of cytomegalovirus (CMV) disease that occurs
despite CMV prophylaxis among liver transplant recipients have been incompletely defined …

Background. Antiviral prophylaxis has been shown to decrease the incidence of
cytomegalovirus (CMV) disease in organ transplant recipients, but whether CMV disease …

Background. The efficacy of valganciclovir used as preemptive therapy for cytomegalovirus
(CMV) disease in liver transplant recipients is not known. Methods. Between 1996 and 2004 …

We assessed the impact of antiviral prophylaxis and preemptive therapy on the incidence
and outcomes of cytomegalovirus (CMV) disease in a nationwide prospective cohort of solid …

Background. Cytomegalovirus (CMV) is a significant cause of morbidity and mortality in solid
organ transplant recipients. Preemptive treatment with antiviral agents of patients with CMV …

Background. The efficacy of pre-emptively administered oral ganciclovir in preventing
cytomegalovirus (CMV) disease has not been documented in liver transplant recipients. We …